BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hoffman R, Zaknoen S, Yang HH, Bruno E, LoBuglio AF, Arrowsmith JB, Prchal JT. An antibody cytotoxic to megakaryocyte progenitor cells in a patient with immune thrombocytopenic purpura. N Engl J Med 1985;312:1170-4. [PMID: 4039036 DOI: 10.1056/NEJM198505023121807] [Cited by in Crossref: 55] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
Number Citing Articles
1 Lippman SM, Durie BG, Garewal HS, Giordano G, Greenberg BR. Efficacy of danazol in pure red cell aplasia. Am J Hematol 1986;23:373-9. [PMID: 3098094 DOI: 10.1002/ajh.2830230409] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 0.3] [Reference Citation Analysis]
2 Canavan BF, Huhn RD, Kim HC, Kosmin M, Sheay W, Saidi P. Concurrent presentation of erythrocytic and megakaryocytic aplasia. Am J Hematol 1996;51:68-72. [DOI: 10.1002/(sici)1096-8652(199601)51:1<68::aid-ajh11>3.0.co;2-7] [Cited by in Crossref: 1] [Article Influence: 0.0] [Reference Citation Analysis]
3 Rice L. Treatment of immune thrombocytopenic purpura: focus on eltrombopag. Biologics 2009;3:151-7. [PMID: 19707404 DOI: 10.2147/btt.2009.2984] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
4 Perdomo J. Role of romiplostim in splenectomized and nonsplenectomized patients with immune thrombocytopenia. Immunotargets Ther 2016;5:1-7. [PMID: 27529057 DOI: 10.2147/ITT.S80648] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
5 Bussel JB, Soff G, Balduzzi A, Cooper N, Lawrence T, Semple JW. A Review of Romiplostim Mechanism of Action and Clinical Applicability. Drug Des Devel Ther 2021;15:2243-68. [PMID: 34079225 DOI: 10.2147/DDDT.S299591] [Reference Citation Analysis]
6 Cheng G. Eltrombopag, a thrombopoietin- receptor agonist in the treatment of adult chronic immune thrombocytopenia: a review of the efficacy and safety profile. Ther Adv Hematol. 2012;3:155-164. [PMID: 23556122 DOI: 10.1177/2040620712442525] [Cited by in Crossref: 26] [Cited by in F6Publishing: 21] [Article Influence: 2.9] [Reference Citation Analysis]
7 Iraqi M, Perdomo J, Yan F, Choi PY, Chong BH. Immune thrombocytopenia: antiplatelet autoantibodies inhibit proplatelet formation by megakaryocytes and impair platelet production in vitro. Haematologica 2015;100:623-32. [PMID: 25682608 DOI: 10.3324/haematol.2014.115634] [Cited by in Crossref: 41] [Cited by in F6Publishing: 39] [Article Influence: 5.9] [Reference Citation Analysis]
8 Ichimata S, Kobayashi M, Honda K, Shibata S, Matsumoto A, Kanno H. Acquired amegakaryocytic thrombocytopenia previously diagnosed as idiopathic thrombocytopenic purpura in a patient with hepatitis C virus infection. World J Gastroenterol 2017; 23(35): 6540-6545 [PMID: 29085203 DOI: 10.3748/wjg.v23.i35.6540] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
9 Arnold DM, Smaill F, Warkentin TE, Christjanson L, Walker I. Cardiobacterium hominis endocarditis associated with very severe thrombocytopenia and platelet autoantibodies. Am J Hematol 2004;76:373-7. [PMID: 15282672 DOI: 10.1002/ajh.20127] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 0.7] [Reference Citation Analysis]
10 Wadenvik H, Stockelberg D, Hou M. Platelet proteins as autoantibody targets in idiopathic thrombocytopenic purpura. Acta Paediatr Suppl 1998;424:26-36. [PMID: 9736215 DOI: 10.1111/j.1651-2227.1998.tb01230.x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 0.4] [Reference Citation Analysis]